Insider Buying: TransMedics Group (NASDAQ:TMDX) Director Acquires $109,057.68 in Stock

TransMedics Group, Inc. (NASDAQ:TMDX) Director David Weill bought 1,336 shares of the business’s stock in a transaction on Friday, September 11th. The stock was bought at an average price of $81.63 per share, with a total value of $109,057.68. Following the purchase, the director owned 16,392 shares in the company, valued at $1,338,078.96. This trade represents a 8.87% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

TransMedics Group Trading Down 0.6%

Shares of TMDX opened at $87.56 on Thursday. TransMedics Group, Inc. has a twelve month low of $60.10 and a twelve month high of $156.00. The stock has a market cap of $3.03 billion, a PE ratio of 22.51, a P/E/G ratio of 1.21 and a beta of 1.90. The company has a quick ratio of 6.07, a current ratio of 6.62 and a debt-to-equity ratio of 1.62. The business’s 50-day moving average price is $82.97 and its 200-day moving average price is $89.26.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $0.44 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.06). The firm had revenue of $189.95 million for the quarter, compared to analysts’ expectations of $184.00 million. TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. TransMedics Group’s revenue was up 20.7% on a year-over-year basis. During the same period in the prior year, the firm posted $0.92 EPS. On average, equities analysts forecast that TransMedics Group, Inc. will post 1.46 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. UBS Group decreased their price target on shares of TransMedics Group from $80.00 to $77.00 and set a “neutral” rating on the stock in a report on Wednesday, August 5th. Piper Sandler reissued an “overweight” rating and set a $100.00 price objective (down from $120.00) on shares of TransMedics Group in a research note on Wednesday, August 5th. TD Cowen restated a “buy” rating and set a $120.00 target price on shares of TransMedics Group in a research report on Tuesday, September 8th. Weiss Ratings upgraded TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, August 31st. Finally, Zacks Research cut TransMedics Group from a “hold” rating to a “strong sell” rating in a report on Monday, July 6th. Five analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, TransMedics Group currently has a consensus rating of “Hold” and a consensus price target of $121.10.

Institutional Trading of TransMedics Group

Several institutional investors and hedge funds have recently made changes to their positions in the stock. WINTON GROUP Ltd increased its stake in TransMedics Group by 52.4% in the second quarter. WINTON GROUP Ltd now owns 18,203 shares of the company’s stock valued at $1,209,000 after acquiring an additional 6,262 shares during the last quarter. Integrated Wealth Concepts LLC lifted its stake in TransMedics Group by 31.3% during the second quarter. Integrated Wealth Concepts LLC now owns 2,877 shares of the company’s stock worth $191,000 after purchasing an additional 686 shares during the last quarter. IFP Advisors Inc boosted its holdings in shares of TransMedics Group by 4.8% in the 2nd quarter. IFP Advisors Inc now owns 4,652 shares of the company’s stock worth $309,000 after purchasing an additional 213 shares in the last quarter. Corient Private Wealth LP boosted its holdings in shares of TransMedics Group by 123.2% in the 2nd quarter. Corient Private Wealth LP now owns 19,285 shares of the company’s stock worth $1,281,000 after purchasing an additional 10,644 shares in the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of TransMedics Group in the 2nd quarter worth about $551,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical technology company focused on improving organ transplantation. The company develops and commercializes organ preservation and transport technologies designed to maintain donor organs in a functioning condition outside the body, potentially supporting evaluation and extending the time available for transplantation.

Its primary product is the Organ Care System (OCS), a portable perfusion platform that circulates oxygenated, nutrient-enriched fluid through donor organs.